Article

The tumor microenvironment in non-small-cell lung cancer.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.
Seminars in radiation oncology (Impact Factor: 3.77). 07/2010; 20(3):156-63. DOI: 10.1016/j.semradonc.2010.01.003
Source: PubMed

ABSTRACT The tumor microenvironment (TME) of NSCLC is heterogeneous with variable blood flow through leaky immature vessels resulting in regions of acidosis and hypoxia. Hypoxia has been documented in NSCLC directly by polarographic needle electrodes and indirectly by assessing tissue and plasma hypoxia markers. In general, elevated expression of these markers portends poorer outcomes in NSCLC. Impaired vascularity and hypoxia can lead to increased metastasis and treatment resistance. Compounds that directly target hypoxic cells such as tirapazamine have been tested in clinical trials for NSCLC with mixed results. Preclinical data, however, suggest other ways of exploiting the abnormal TME in NSCLC for therapeutic gain. The inhibition of hypoxia-inducible factor-1alpha or vascular endothelial growth factor may increase local control after radiation. Inhibitors of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/Akt pathway, such as erlotinib or PI-103, may "normalize" tumor vessels, allowing for increased chemotherapy delivery or improved oxygenation and radiation response. To select patients who may respond to these therapies and to evaluate the effects of these agents, a noninvasive means of imaging the TME is critical. Presently, there are several promising modalities to image hypoxia and the tumor vasculature; these include dynamic perfusion imaging and positron emission tomography scanning with radiolabled nitroimidazoles.

Download full-text

Full-text

Available from: Edward Elliot Graves, Jul 05, 2015
0 Followers
 · 
91 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective is to validate the combination of 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) and (18)F-fluorodeoxyglucose ((18)F-FDG) as a "novel" positron emission tomography (PET) tracer for better visualization of cancer cell components in solid cancers than individual radiopharmaceutical. Nude mice with subcutaneous xenografts of human non-small cell lung cancer A549 and HTB177 cells and patients with lung cancer were included. In ex vivo study, intratumoral radioactivity of (18)F-FDG, (18)F-FLT, and the cocktail of (18)F-FDG and (18)F-FLT detected by autoradiography was compared with hypoxia (by pimonidazole) and proliferation (by bromodeoxyuridine) in tumor section. In in vivo study, first, (18)F-FDG PET and (18)F-FLT PET were conducted in the same subjects (mice and patients) 10 to 14 hours apart. Second, PET scan was also performed 1 hour after one tracer injection; subsequently, the other was administered and followed the second PET scan in the mouse. Finally, (18)F-FDG and (18)F-FLT cocktail PET scan was also performed in the mouse. When injected individually, (18)F-FDG highly accumulated in hypoxic zones and high (18)F-FLT in proliferative cancer cells. In case of cocktail injection, high radioactivity correlated with hypoxic regions and highly proliferative and normoxic regions. PET detected that intratumoral distribution of (18)F-FDG and (18)F-FLT was generally mismatched in both rodents and patients. Combination of (18)F-FLT and (18)F-FDG appeared to map more cancer tissue than single-tracer PET. Combination of (18)F-FDG and (18)F-FLT PET imaging would give a more accurate representation of total viable tumor tissue than either tracer alone and would be a powerful imaging strategy for cancer management.
    Translational oncology 12/2013; 6(6):775-83. DOI:10.1593/tlo.13577 · 3.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anticancer nanomedicine was coined to describe anticancer delivery systems such as polymer conjugates, liposomes, micelles, and metal nanoparticles. These anticancer delivery platforms have been developed with the enhanced permeability and retention (EPR) effect as a central mechanism for tumor targeting. EPR based nanomedicine has demonstrated, beyond doubt, to selectively target tumor tissues in animal models. However, over the last two decades, only nine anticancer agents utilizing this targeting strategy have been approved for clinical use. In this review, we systematically analyze various aspects that explain the limited clinical progress yet achieved. The influence of nanomedicine physicochemical characteristics, animal tumor models, and variations in tumor biology, on EPR based tumor targeting is closely examined. Furthermore, we reviewed results from over onehundred publications to construct patterns of factors that can influence the transition of EPR based anticancer nanomedicine to the clinic.
    Journal of Controlled Release 07/2012; 164(3). DOI:10.1016/j.jconrel.2012.07.013 · 7.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thermal characterization and optimization of RF and MW power transistors represents a significant challenge to maximize effective power density and minimize thermal memory and its impact on linearity. We describe a novel loadpull system with an integrated infrared thermal imaging system that allows real-time observation of steady-state die temperature versus source/load impedance. Spatial resolution of 2 um allows examination of individual emitter fingers for HBT technologies, while the 2x2 mm field of vision allows examination of an entire die. The system is capable of presenting contours of spatial instantaneous temperature, spatial average temperature, and associating source/load impedance points with images representing full-color isotherms. Thermal measurements of an HJFET are shown to illustrate the capability of the new system.
    ARFTG Conference Digest Spring, 2004. 63rd; 02/2004